List of Peptide Therapies Companies in Indiana - 2

Search through the full list with powerful filtering options

Company	About
INCOG BioPharma Fishers, Indiana	INCOG BioPharma Services is a CDMO with an unparalleled client-centric approach supporting biopharmaceutical partners' clinical and commercial requirements. The company has built a state-of-the-art facility with 90,000 square feet to support biopharmaceutical companies. INCOG BioPharma Services also added 100 million units of syringe/cartridge capacity and announced a collaboration with Resilience to expedite manufacturing of biological drug substance and drug product.
MBX Biosciences Carmel, Indiana, United States of America	MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.

Company

About

INCOG BioPharma

Fishers, Indiana

INCOG BioPharma Services is a CDMO with an unparalleled client-centric approach supporting biopharmaceutical partners' clinical and commercial requirements. The company has built a state-of-the-art facility with 90,000 square feet to support biopharmaceutical companies. INCOG BioPharma Services also added 100 million units of syringe/cartridge capacity and announced a collaboration with Resilience to expedite manufacturing of biological drug substance and drug product.

MBX Biosciences

Carmel, Indiana, United States of America

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™). PEPs are designed to overcome key limitations of native peptide therapeutics to deliver superior pharmacologic properties. MBX is advancing a pipeline of PEP candidates to address the unmet needs of people with endocrine disorders. The company’s lead product candidate, MBX 2109 for the treatment of hypoparathyroidism, is currently in a Phase 1 clinical trial. Members of MBX’s leadership team have collaborated over several decades on the discovery, development, and commercialization of highly successful endocrine therapeutics including Forteo® and Humalog®. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates and OrbiMed.